ACUR:OTC-Acura Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.01

Change

0.00 (0.00)%

Market Cap

USD 0.65M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ACUR Stock Forecast & Price:
Based on the Acura Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Acura Pharmaceuticals Inc is not available over the next 12 months. Acura Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acura Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Acura Pharmaceuticals Inc’s stock price was USD 0.01. Acura Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -98.00% over the last year.

No recent analyst target price found for Acura Pharmaceuticals Inc
No recent average analyst rating found for Acura Pharmaceuticals Inc

About Acura Pharmaceuticals Inc (ACUR:OTC)

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the m ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY Merck KGaA ADR

N/A

USD71.35B 21.24 12.95
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD69.08B 21.20 12.95
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD41.88B 30.44 0.07
HLUYY H Lundbeck A/S ADR

N/A

USD21.84B 28.95 3.09
SGIOF Shionogi & Co. Ltd

N/A

USD14.52B 17.68 0.07
SGIOY Shionogi & Co Ltd ADR

N/A

USD14.12B 17.25 0.07
ESALY Eisai Co Ltd ADR

N/A

USD11.91B 35.09 0.11
ESALF Eisai Co. Ltd

N/A

USD11.81B 35.90 0.11
GNHAF Vifor Pharma AG

N/A

USD11.68B 77.46 17.65
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ACUR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -98.00% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.00% 3% F 2% F
Trailing 12 Months  
Capital Gain -98.00% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.00% 6% F 3% F
Trailing 5 Years  
Capital Gain -97.78% 17% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.78% 17% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain 21.16% 67% D+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.16% 66% D 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 69.76% 47% F 40% F
Risk Adjusted Return 30.34% 77% C+ 59% F
Market Capitalization 0.65M 19% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 56% F 70% C-
Price/Book Ratio 2.41 36% F 37% F
Price / Cash Flow Ratio -0.91 55% F 63% D
EV/EBITDA -0.74 51% F 60% D-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -92.61% 22% F 11% F
Return on Assets -38.42% 30% F 19% F
Debt to Equity Ratio -1.78% 76% C 86% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.73 53% F 53% F
Short Percent 1.20% 33% F 42% F
Beta 0.35 75% C 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector